Traditionally, patients with muscle-invasive bladder cancer (MIBC) face lengthy diagnostic-to-treatment timelines exceeding 130 days. The late-breaking BladderPath trial introduced pre-treatment MRI, reducing this to 95 days while halving relapse risk and lowering overall costs. At the European Society for Medical Oncology (ESMO) 2025 congress, Prof Nicholas D. James (Professor, Prostate and Bladder Cancer Research, Institute of Cancer Research; Consultant Clinical Oncologist, Royal Marston Hospital, London, UK) presented results demonstrating that incorporating MRI scans early in the treatment pathway for MIBC significantly accelerates care and improves outcomes. The study suggests that early MRI allows for more precise staging, targeted interventions and streamlined surgical planning, offering both patients and healthcare systems a more efficient and effective pathway for bladder cancer management.
The late-breaking abstract, ‘Randomized Comparison of upfront Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Final survival analysis from the BladderPath trial’ (LBA111) was presented at the European Society for Medical Oncology (ESMO) congress on 17th-21st October 2025 in Berlin, Germany.
Q1. What are the main limitations of the current staging pathway for MIBC, and what was the rationale behind the BladderPath trial?
Aside from flexible cystoscopy, bladder cancer staging has remained largely unchanged for a century. Patients presenting with hematuria and a bladder mass undergo transurethral resection of bladder tumour (TURBT) – a procedure that simultaneously provides tissue diagnosis, staging and treatment. While sufficient for non-muscle-invasive disease, TURBT often fails to stage muscle-invasive tumours accurately because larger, disordered tumours may not yield muscle in the specimen. This inefficiency can delay treatment, with typical timelines exceeding 130 days. The BladderPath trial was designed to test whether early MRI could improve staging accuracy, prioritize high-risk patients and streamline the pathway.
Q2. What was the study design and eligibility criteria?
BladderPath enrolled patients whose tumours were uncertain for invasiveness after initial cystoscopy. Those confidently non-muscle-invasive proceeded directly to TURBT, while others underwent pre-treatment multi-parametric MRI (mpMRI) to guide biopsies and treatment decisions. The trial was structured in three phases: feasibility, pathway optimization and analysis of time to definitive therapy (surgery, chemotherapy or radiotherapy).
Q3. What were the key takeaways from the results, especially the final survival analysis shared at this year’s ESMO?
With at least two years of follow-up, hazard ratios for failure-free, bladder cancer-specific and overall survival all favoured the MRI arm. Bladder cancer-specific survival reached statistical significance, with MRI halving the risk of relapse. MRI enhanced treatment decision-making: complex cases were fast-tracked to senior surgeons, reducing delays without mislabeling patients. Additionally, MRI-informed TURBTs were more targeted, optimizing theatre time while maintaining high diagnostic accuracy. The primary endpoint was time to treatment. Pre-trial audits showed average timelines of 130 days; the control arm outperformed this and trial participation reduced this to 95 days. On the MRI-informed arm, this dropped by a further 42 days, even though 85% still underwent TURBT. Hence by integrating MRI before TURBT, we cut the time to definitive treatment by six weeks.
In the NHS, MRI is less costly than TURBT. By eliminating 15% of TURBT procedures, the trial achieved net savings. MRI also reduced theatre load – critical in high-volume centers – with a modest increase in radiology demand, especially when considered alongside the much larger number of prostate MRIs carried out in uro-oncology services. This modest increase in scans is manageable compared to the benefit of faster, targeted treatment, improved outcomes and reduced morbidity.
Q5. Are there any challenges to consider adopting upfront mpMRI to stage new bladder cancers more widely?
Adoption varies across regions. While major London centres have begun implementing MRI-informed pathways, peripheral hospitals often remain reliant on traditional one-size-fits-all TURBT. There are parallels with the adoption of prostate MRI and evidence supporting faster, safer and more cost-effective care tends to drive uptake over time. As data accumulate, wider adoption of MRI-informed pathways is expected to become standard practice.
Disclosure: Nicholas James has no financial or non-financial conflicts of interest to declare in relation to this interview.
This content has been developed independently by Touch Medical Media for touchONCOLOGY. It is not affiliated with the European Society for Medical Oncology (ESMO). Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Cite: ESMO25 BladderPath: Early MRI cuts time-to-treatment and relapse risk in muscle-invasive bladder cancer. touchONCOLOGY. October 24th, 2025
Related content
- ESMO25 Presidential Late-breaker: KEYNOTE-905 delivers breakthrough results in cisplatin-ineligible MIBC
- ESMO25 late-breaker: LenCabo head-to-head highlights lenvatinib-everolimus benefit after immunotherapy in metastatic ccRCC
- #ASCO25 highlights: Q&A with Prof Dickon Hayne: Can mitomycin boost BCG in high-risk NMIBC?
